EP1199306A1 — Biarylurea derivatives
Assigned to MSD KK · Expires 2002-04-24 · 24y expired
What this patent protects
The present invention relates to a compound of Formula (I) and the manufacturing method(s) thereof and the use thereof: ,wherein: Ar is a nitrogen-containing heteroaromatic ring group; X and Z are each a carbon atom, and so on; Y is CO, and so on; R 1 is a hydrogen atom, and s…
USPTO Abstract
The present invention relates to a compound of Formula (I) and the manufacturing method(s) thereof and the use thereof: ,wherein: Ar is a nitrogen-containing heteroaromatic ring group; X and Z are each a carbon atom, and so on; Y is CO, and so on; R 1 is a hydrogen atom, and so on; R 2 and R 3 are each a hydrogen atom, and so on; R 4 and R 5 are each a hydrogen atom, and so on; and the formula --- is a single bond or a double bond. According to the present invention, the compound of the present invention can provide Cdk4 and/or Cdk6 inhibitors for treating malignant tumors, because the compounds of the present invention exhibit a prominent growth inhibitory activity against tumor cells.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.